Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.56%
#3 Cysic Cysic +41.67%
#4 Glidr Glidr +36.41%
#5 Walrus Walrus +29.37%
#6 Humanity Humanity +23.38%
#7 Codatta Codatta +16.38%
#8 Enso Enso +16.32%
#9 Tutorial Tutorial +15.81%
#10 Ribbita by Virtuals Ribbita by Virtuals +14.43%
Coin of the day
EXOD EXOD
Innstillinger
Språk
NORSK
Valuta
USD
Tema
ViewRay, Inc. ViewRay, Inc.

ViewRay, Inc.

VRAY
Rangering i aksjer #37058
ViewRay, Inc. specializes in the development, production, and global... ViewRay, Inc. specializes in the development, production, and global distribution of advanced radiation therapy systems that leverage magnetic resonance imaging (MRI). These integrated systems are utilized to both image and deliver treatment for cancer patients in various countries, including the United States, France, Taiwan, and the United Kingdom. The company's key product, MRIdian, is an MRI-guided radiation therapy solution engineered to address critical concerns during treatment, such as beam distortion and potential skin toxicity. ViewRay's client base spans a diverse range of medical facilities, including university research and teaching hospitals, local community hospitals, private medical practices, government institutions, and independent cancer treatment centers. MRIdian systems are sold to these clients via ViewRay's direct sales force and through its established distribution channels. The company was founded in 2004 and operates out of its main office in Oakwood, Ohio.
Aksjekurs
$0.014
Sist synkronisert: 2023-08-21
Markedsverdi
$2.07M
Endring (1 dag)
-1.41%
Endring (1 år)
0.00%
Land
US
Handel ViewRay, Inc. (VRAY)

Kategori

Healthcare
P/E-forhold for ViewRay, Inc. (VRAY)
P/E-forhold per 2026 TTM: 0
Ifølge ViewRay, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for ViewRay, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.64 -
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.